• 임상 CRO
• 컨설팅
• DCT

Neurophet’s Imaging CRO strength lies in combining central imaging core lab operations, AI-powered neuroimaging analysis, regulatory-grade imaging workflows, and clinical trial execution support. Rather than functioning only as an imaging software provider, Neurophet can position itself as an end-to-end neuroimaging partner supporting sponsors from study design to imaging endpoint assessment. A key differentiator is Neurophet’s focus on neurology and neurodegenerative disease trials, particularly Alzheimer’s disease and related disorders. The company’s platform covers both MRI and PET modalities, supporting quantitative analysis of brain atrophy, white matter hyperintensity, amyloid/tau/FDG PET biomarkers, ARIA-related imaging findings, lesion tracking, and longitudinal disease progression. This allows sponsors to generate imaging-based evidence for patient selection, safety monitoring, efficacy evaluation, and regulatory decision-making.